NCT03719898 · Interventional trial
Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma
Overall registry status Withdrawn
Phase 2
Conditions Anaplastic Large Cell Lymphoma, ALK-Positive
Delaware Valley sites
- Fox Chase Cancer Center · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory